Bio-Related Compositions

JP7580392B2Active Publication Date: 2024-11-11BIORELEVANT COM LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021558961
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-04
Filing Date
2020-04-06
Publication Date
2024-11-11
Estimated Expiration
2040-04-06

AI Technical Summary

Benefits of technology

及び産業上の利用可能性をさらに裏付ける(図11及び図12を参照)。試験媒体は、平衡に24時間以上要し得る平衡可溶性試験に特に有用である。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580392000014
    Figure 0007580392000014
  • Figure 0007580392000015
    Figure 0007580392000015
  • Figure 0007580392000016
    Figure 0007580392000016
Patent Text Reader

Abstract

1. A biorelevant precursor composition suitable when dispersed, diluted, or suspended in an aqueous medium to simulate the gastric fluids of a mammalian species in a fed state, the biorelevant precursor composition comprising a substantially solid / solid-like concentrate, a viscous gel-like concentrate, or a liquid fat dispersion / concentrate, comprising at least one major component selected from each of the following groups of major components: i) triglycerides and / or diglycerides and / or monoglycerides or any combination thereof in an amount of 1-70% by weight; ii) lecithin and / or lysolecithin in an amount of 1-45% by weight; iii) carbohydrates in an amount of 15-70% by weight; and iv) water or other aqueous medium in an amount of 1-70% by weight; wherein the weight ratio of total fat (one or more major components from each of groups i) and ii) combined):total carbohydrates (one or more major components from group iii) combined) is 20:1 to 1:20; The present invention relates to a method for preparing a soluble collagen matrix comprising: a main component having a weight ratio of 45:1 to 1:45 of lecithin and / or lysolecithin; and further comprising: (i) fatty acids (0.01 to 15% by weight); (ii) bile acids / salts (0.01 to 3% by weight); (iii) enzymes (0.01 to 2% by weight); (iv) cholesterol, sterols (0.01 to 5% by weight); (v) buffers (0.01 to 4% by weight); (vi) osmotic agents (0.01 to 10% by weight); (vii) proteins (collagen, protein (viii) mucin (0.1 to 5% by weight); (ix) viscosity modifier (0.1 to 5% by weight); and (x) at least one additional ingredient selected from at least one of a) antioxidants, b) chelating agents, c) buffers (inorganic or organic), d) antimicrobial agents, etc., all percentages being by dry weight. Methods for making these compositions are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention is in the field of drug solubility, dissolution and biorelevance testing. The present invention describes concentrates and dissolution compositions for reconstituting an in vitro biorelevant test medium. The in vitro medium contains biorelevant dietary components and shares physical and chemical parameters of gastric fluid after food consumption, particularly human gastric fluid. The synthetic in vitro medium mimics fed state gastric fluid and can be used for biorelevant solubility, dissolution and stability profiling of drugs and dosage forms, in vitro comparative dissolution testing, in vitro-in vivo correlation, and simulated gastric fluid in vitro studies of the effect of food on drugs. [Background technology]

[0002] The major dietary components of foods, including fats (oils, such as glycerides and lipids, such as phospholipids), carbohydrates, and proteins, provide nutrients and support biological functions.

[0003] In the stomach, where ingested food is stored and digested, lipophilic components, e.g., drugs, can be solubilized in (partially) digested dietary fat along with food components, gastric enzymes and secretions before the chyme is transferred to the upper small intestine. The upper small intestine is composed of the duodenum, ileum, and jejunum, where further digestion and absorption occurs, catalyzed by food-responsive enzymes. Furthermore, wetting and solubilization of lipophilic components, e.g., drugs, is assisted by lipolysis products associated with biological surfactants, e.g., bile salts and lecithin. The residence of the chyme containing partially digested food in the stomach before entering the upper small intestine can take from about 30 minutes to 6 hours or more, depending on the food components and the drug / dosage form.

[0004] References herein to the gastrointestinal (GI) tract include the stomach and upper small intestine regions. The present invention relates to simulated fed gastric fluid induced, for example, by a high fat meal (e.g., containing 55g-65g fat) or a low fat meal (e.g., containing 11g-14g fat) as recommended by the FDA (Draft Guidance for Industry 2019) to evaluate the effect of food on drugs. The present invention provides a fed gastric medium for in vitro solubility and dissolution testing, which may aid in understanding how drugs are released from dosage forms in the stomach after a meal. The biorelevant simulated fed gastric fluid of the present invention for use in in vitro dissolution testing is referred to as FEDGAS.

[0005] These tests can help predict the effect of food on drug absorption, which can be positive, negative, or remain the same. Solubility and dissolution / dissolution rate are important parameters for oral drug absorption and subsequent bioavailability. Solubility and dissolution tests in FEDGAS fed state dissolution medium compared to fasted state simulated gastric fluid can help predict whether oral absorption may be affected by food.

[0006] These tests can also be used to mitigate risk in bioequivalence studies by confirming that the dissolution profile of the generic test product matches that of the (inventor's) drug listed in the reference list.

[0007] The physicochemical properties of the gastric environment, such as pH, buffering capacity, osmolality, ionic strength and motility, can change significantly in response to food intake. Pharmacokinetic parameters such as Cmax, Tmax, and AUC can be correlated with solubility and dissolution profiles in fed-state simulated gastric fluid (FEDGAS). In combination with biorelevant in vitro dissolution studies in simulated fed and fasted intestinal fluids, combined with physiologically based pharmacokinetic modeling, drug bioavailability can be predicted. Modified and sustained release dosage forms with pH-dependent coatings in the GI environment, e.g., pH 4.5-6.5, can have different disintegration times and drug release patterns in vivo due to fed-state gastric fluid, which typically spans a wide physiological pH range. This behavior is reflected in in vitro dissolution media (pH 3, pH 4.5, and pH 6.0) studies using fed-state simulated gastric fluid (FEDGAS). The present invention is also suitable for in vitro dissolution testing of other modified release formulations, including, but not limited to, diffusion systems, dissolution systems, osmotic systems, ion exchange resins, suspension systems, bioadhesive systems and matrix systems.

[0008] The physicochemical stability of FEDGAS is unchanged in in vitro dissolution testing for 24 hours or more at 37° C. Thus, sustained release dosage forms can be tested in FEDGAS dissolution medium for 24 hours or more at 25° C. and 37° C., further supporting the advantages and industrial applicability of the present invention compared to prior art dissolution testing that is typically limited to 8 hours (see FIGS. 11 and 12). The test medium is particularly useful for equilibrium solubility testing, which may require 24 hours or more for equilibrium.

[0009] Therefore, the present invention focuses on a biorelevant in vitro gastric medium with reproducible criteria (e.g. particle size and filterability) that more closely mimics and simulates the physicochemical properties of human gastric fluids after food ingestion.

[0010] The composition and physical properties of GI fluids in the fed state vary with the type of food (see standard high-fat and low-fat meals in the Food and Drug Administration (FDA) recommended Assessing the Effects of Food on Drugs in INDs and NDAs (2019 draft guidance)) and the length of time in the stomach. In the fasted state, without food, gastric fluids typically appear at a low pH, around pH 1-3. After a meal, the pH rises to about pH 6 and then returns to base levels of pH 1-3 for up to about 6 hours. Changes in gastric pH primarily affect weak acids and weak bases, with the elevated values ​​in the fed state promoting the dissolution of acids and decreasing the dissolution of bases at pH 6, but the reverse can be true at pH 3.

[0011] Compendial media that simulate gastric fluids (such as in the USP and EP) do not contain physiological / biological components (such as fat) and are generally not suitable for biorelevant solubility and dissolution testing of water-insoluble drugs.

[0012] In one embodiment, the in vitro fed state dissolution medium (FEDGAS) derived from the precursor concentrate mimics in vivo gastric fluid after, for example, ingestion of an FDA high-fat meal, which is the standard recommended high-fat meal ingested to perform in vivo testing of food effects with drugs and is bioequivalent for in vivo food effect human studies.

[0013] In another embodiment, the fed state gastric medium (FEDGAS) for in vitro dissolution testing contains a specific amount of fat present in a meal.

[0014] In vitro dissolution media prepared from the precursor concentrate can provide amounts of fat similar to the amount of fat in an ingested diet (1 g to 200 g).

[0015] It should be understood that the in vitro fed state gastric test medium described in the present invention has practical and industrial applicability not limited to solubility and dissolution testing. For example, the in vitro biorelevant medium can be used to test the compatibility of gastric implants, devices, and bands, and to evaluate the stability of probiotic and vitamin products to see if they are unstable and can remain in the stomach with food.

[0016] The present invention relates to the development and provision of in vitro fed state simulated gastric fluids (FEDGAS) based, for example, on FDA high-fat and low-fat diets and other dietary variations (e.g., Klein et al., "Media to simulate the postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts," Journal of pharmacy and pharmacology 56(5)(2004):605-610). These are recommended for in vivo human studies to evaluate the effect of food on drugs, for example, (i) high fat high calorie, (ii) medium fat medium calorie, (iii) low fat low calorie, and (iv) low or high calorie meals with similar fat content.

[0017] F.Baxevanis et al., European Journal of Pharmaceutics and Biopharmaceutics, Vol.107, 2016, 234-248, describes the physicochemical factors that affect drug solubility and dissolution in various simulated gastric fluids after food. Simulated fed-state gastric fluid for dissolution testing and drug analysis techniques are comprehensively reviewed. Fed conditions can have a significant effect on in vitro drug dissolution and subsequent absorption profile. It was emphasized that drug analysis in fed-state gastric media in the prior art can be challenging as most analytical protocols used are time-consuming and labor-intensive. Due to the physical properties and chemical composition of the prior art dissolution media, filterability and suitable buffers (avoiding precipitation and allowing 100% drug recovery) are pressing issues that require practical consideration in in vitro testing. Clearly, there is an unmet need for more user-friendly biorelevant dissolution media that can better mimic post-meal gastric fluids and avoid identified issues such as compatibility, precipitation, filterability and drug recovery at physiological gastric fed pH (e.g., pH 1.5-7.5) in prior art in vitro dissolution tests.

[0018] In Jantratid et al., Pharmaceutical Research, Vol. 25, No. 7, 2008, 1663-1676, a snapshot fed-state simulated medium (FeSSGF) has been proposed for dissolution testing, containing 50% acetate buffer and 50% UHT milk (maximum 3.5% fat in full fat UHT milk), resulting in a fat content of 1.75% at pH 5.0 in FeSSGF. The compositions of the three "snapshot" media (early, mid, late) to simulate fed-state simulated gastric fluids corresponding to pH 6.4, 5, and 3 of Jantratid et al. are shown in Table 2. FeSSGF is an acronym given to identify the simulated gastric fluids of the mid-term fed-state at pH 5 between 75 and 165 minutes after feeding. However, this composition, referred to as intermediate (FeSSGF) in the aforementioned Table 2, basically contains milk / buffer and does not contain the fat content of the FDA high-fat meal, and is affected by variations in the quantity and quality of fat in milk. Furthermore, the physical stability is insufficient (see photo 4 of Jantratid et al.). Table 4 of Jantratid et al. shows dissolution media for simulating the upper small intestine in the fed state, whereas the present invention describes media for simulating the stomach in the fed state. For the avoidance of doubt, FEDGAS for simulating gastric fluid in the fed state and FeSSIF for simulating upper small intestinal fluid in the fed state (Table 4 of Jantratid et al.) in the present invention are not similar in vitro dissolution compositions.

[0019] US 2016 / 0299113 describes solid compositions for preparing biorelevant dissolution media simulating fasted and fed intestinal fluids for dissolution testing. The disclosure teaches a molar ratio of bile salts to phospholipids of 1:1 to 20:1, so the product contains amounts of bile salts outside the scope of the present invention.

[0020] Conventional in vitro dissolution testing in simulated gastric fluid includes EnsurePlus® (a commercial "protein milkshake" drink) which contains fat (4.6% w / v total fat), protein and carbohydrate to mimic fed state gastric fluid. This medium is not suitable for in vitro dissolution testing because, like full fat milk, it is not stable in the physiological pH range of the fed stomach and filtration is very difficult, for example using a 0.45 micrometer filter using a GD / X glass microfiber (GMF) syringe filter.

[0021] Similarly, FeSSGF, which mimics fed-state gastric fluids, is not suitable as an in vitro dissolution medium (see above) because it is difficult to filter and is physically unstable in the physiological gastric pH range. Furthermore, FeSSGF does not contain the specific amount of fat found in the FDA high-fat diet.

[0022] A further example of a prior art FeSSGF medium for dissolution studies is the "Fed State Simulated Gastric Emulsion" (FeSSGEm), a mixture of acetate buffer and Lipofundin MCT® made up in a ratio of 82.5:17.5. The medium contains triglycerides (1.75%), egg lecithin (about 0.21%) and glycerin (0.44%). Importantly, this composition does not contain the amount of fat and carbohydrates recommended, particularly the recommended FDA high fat meal, and may be unstable in the pH range of the fed stomach (Klein, In vitro lipolysis assay as a prognostic tool for the development of lipid based drug delivery systems: Martin Luther Universitat Halle- Wittenberg; 2013). [Prior art documents] [Patent documents]

[0023] [Patent Document 1] US Patent Application Publication No. 2016 / 0299113 [Non-patent literature]

[0024] [Non-Patent Document 1] Klein et al., “Media to simulate the postprandial stomach I.Matching the physicochemical characteristics of standard breakfasts,” Journal of pharmacy and pharmacology56(5)(2004):605-610 [Non-Patent Document 2] F. Baxevanis et al.,European Journal of Pharmaceutics and Biopharmaceutics,Vol.107,2016,234-248 [Non-Patent Document 3] Jantratid et al.,Pharmaceutical Research,Vol.25,No.7,2008,1663-1676 [Non-Patent Document 4] Klein,In vitro lipolysis assay as a prognostic tool for the development of lipid based drug delivery systems:Martin Luther Universitat Halle-Wittenberg;2013 Summary of the Invention [Problem to be solved by the invention]

[0025] The physicochemical properties and performance of various fed state gastric dissolution media are summarized and compared in Table 1 below. It will be appreciated that Table 1 shows the fed state gastric media of the present invention, FEDGAS, in which all boxes (+) are checked, thus clearly indicating that FEDGAS meets all of the identified parameters that are not included in the known prior art media (-).

[0026] [Table 1]

[0027] As shown in Table 1, liquid enteral and parenteral products were investigated as in vitro dissolution media to mimic fed-state conditions in the stomach, along with an actual homogenized standard FDA meal. Nevertheless, the extraction issues and time required to analyze the drug require a more user-friendly simulated fed-state gastric fluid that is compatible with standard USP dissolution apparatus and recommended methods. There is little information to suggest that prior art dissolution media are fit for the purpose of drug dissolution studies lasting more than 4 hours at 37°C and are also compatible in the physiological gastric fed-state pH range of pH 7.5 to pH 1.5 during the "early", "mid" and "late" stages of digestion in the stomach. Testing at three typical pHs in the pH range 7.5 to 1.5 is required so that the solubility and dissolution profile can be monitored while the drug is in contact with food in the fed stomach.

[0028] The objective of the present invention is to provide an in vitro dissolution medium containing dietary components, primarily including fat and carbohydrate, that capture and replicate the physicochemical properties of gastric fluids after a meal. Furthermore, the dissolution composition typically contains specific amounts of fat and carbohydrate present in the FDA recommended high-fat, high-calorie standard meal ingested when in vivo BA / BE (bioavailability / bioequivalence) studies and food effects on drugs in humans are conducted. There remains an unmet need for an in vitro dissolution medium containing biorelevant components that replicate or can replicate the physical and chemical properties of human gastric fluids in the fed state after ingestion of meals with variable fat content ranging from 1 g to 200 g.

[0029] The present invention discloses an in vitro biorelevant dissolution medium dedicated to testing food effects in the stomach after a meal, including but not limited to solubility, stability, dissolution profiling of new chemical entities as well as generic drugs, dissolution comparison of dosage forms to support BA / BE studies, suitability of probiotics, nutraceuticals, vitamins, gastric implants, device performance and safety testing in the pH range of fed stomach contents. In addition to the benefits of labor saving, consistency and reproducibility, the fed state gastric medium is compatible with filtration after incubation, which allows HPLC analysis of drug or degradation products in the filtrate as highlighted in the prior art (Baxevanis et al.) mentioned above.

[0030] In comparison to media described in the prior art (e.g., FeSSGF), the biorelevant fed state gastric media (FEDGAS) described herein is more suitable for in vitro dissolution studies and in vitro-in vivo correlations, and the resulting FEDGAS has been shown to mimic in vivo gastric fluids, e.g., after consumption of an FDA standard high fat meal.

[0031] The term "biorelevant concentrate / composition" is also referred to herein as "biorelevant precursor composition" or "biorelevant precursor concentrate." [Means for solving the problem]

[0032] The inventors have found that an in vitro gastric dissolution medium containing dispersed fats along with carbohydrates mimics the properties of gastric fluids, for example after consumption of a high fat meal. The fats may include triglycerides, diglycerides, monoglycerides, lecithin and / or lysolecithin.

[0033] The present invention provides substantially solid / solid-like concentrates, substantially clear to opaque viscous gel-like compositions (concentrates), and fat dispersions / liquid concentrates containing high levels of fat and carbohydrates, where the combination of high energy input and ingredients including primarily triglycerides, lecithin and / or lysolecithin and carbohydrates produces fat dispersions (concentrates) that are easily water dispersible. Dilution of these easily water dispersible concentrates with aqueous media, including, for example, buffers and osmolarity components, results in fed state dissolution media and fat aggregates less than 500 nm Z-average diameter (FIG. 9). Unexpectedly, exemplary physicochemical stability is obtained in in vitro dissolution tests for at least 24 hours after preparation of the media, and long-term stability of the concentrates for at least 12 months at room temperature.

[0034] Suitable buffers are selected from, but not limited to, acetate, phosphate, and citrate buffers to span the fed state physiological gastric pH range of 1.5 to 7.5. Particularly useful pH parameters are pH 3.0, pH 4.5, pH 5.0, and pH 6.0, which reflect the pH of human gastric fluids after ingestion of a high or low fat meal at different residence times of food in the fed stomach. In vitro dissolution media prepared from the concentrate compositions also avoid analytical problems such as filtration and pH incompatibility at fed state gastric pH of pH 1.5 to pH 7.5, as identified in the prior art and shown in Table 1.

[0035] The process involves high energy input, controlled evaporation, and / or careful addition of targeted amounts of water.

[0036] The processing steps include: (i) High energy input, such as high pressure emulsification, sufficient to produce finely divided, substantially uniform fat particles / aggregates with an average diameter of less than 1000 nm, typically less than about 500 nm; (ii) A step of controlled evaporation after addition of water containing at least one carbohydrate such as a sugar or direct control of the addition of water containing at least one carbohydrate such as a sugar, wherein the water content of the resulting target composition is closely controlled between 1.0% and 70.0% by weight, typically between 1.0% and 10.0% for solid / solid-like concentrates, typically between 10% and 25% for viscous gel-like concentrates and typically between 25% and 70% for fat dispersions / liquid concentrates.

[0037] The processes and process steps detailed herein form further aspects of the present invention.

[0038] The resulting substantially solid / solid-like concentrates, viscous gel-like concentrate compositions and liquid fat dispersion concentrates, as described, are concentrates as well as precursors for preparing fed state, biorelevant dissolution media.

[0039] The test medium can be prepared by dispersing, diluting, or suspending the readily water-dispersible precursor concentrate in an aqueous medium using simple mixing (e.g., a magnetic stirrer) without any high energy input. The resulting test medium is a stable, uniformly dispersed fat dispersion that can be easily filtered through a 0.45 micrometer filter.

[0040] Media containing uniformly finely dispersed fat particles are suitable for dissolution testing at pH 1.5 to about pH 7.5, thereby providing pH compatibility in this physiological pH range of the fed state stomach that has prevented wider use of prior art fed state gastric dissolution media. Furthermore, in vitro dissolution and food effect testing using conventional dissolution apparatus, such as, but not limited to, USP Dissolution Apparatus 2, have been unsuccessful due to pH incompatibility, filterability and reproducibility limitations associated with, for example, milk and enteral surrogates.

[0041] Dissolution tests may use volumes of 0.5 mL to 20 mL, more typically 5 mL to 10 mL, to assess kinetic and equilibrium solubilities determined, for example, by shake flask methods.

[0042] Vessel volumes of 250 mL to 1 L, preferably 750 mL to 900 mL, may be used for standard USP dissolution apparatus 1 and 2. Small dissolution vessels, typically 50 to 200 mL, may be used for in vitro dissolution testing.

[0043] For example, in tests requiring flow-through studies using the USP dissolution apparatus4, the volume of dissolution medium can be increased to several liters if open-loop testing is required.

[0044] The development of a suitable biorelevant in vitro fed-state gastric dissolution medium that can be used with simple and robust analytical methods such as HPLC, which requires separation of undissolved drug by filtration, would introduce a useful means of testing the effect of food on drugs and pharmaceuticals. Several fed-state media such as milk, nutritional drinks, or fed-state simulated gastric fluid (FeSSGF) at pH 5 have been attempted in the prior art to mimic the human postprandial state (Table 1, Table 2). However, to date, none have provided a satisfactory representation of real fed-state gastric fluid after an FDA meal, making them impractical for routine laboratory use. The proposed biorelevant dissolution medium (FEDGAS) of the present invention more accurately mimics human gastric fluid after a high-fat meal, corresponding to a pH of 6.0 in about 30 minutes and returning to a base level of pH 3.0 at about 6 hours after feeding. However, due to changes in the composition of the meal and inter- and intra-variability depending on the physiology of the human stomach in the fed state, the pH may span a wider range, e.g., pH 7.5 to pH 1.5. In one aspect, the present invention provides biorelevant compositions in concentrates that, upon dispersion or dilution in an aqueous medium, are suitable for preparing an in vitro fed-state dissolution medium to simulate the fed-state gastric fluids of a mammalian species.

[0045] In one embodiment of the present invention, the aqueous medium for dispersing or diluting the biorelevant concentrate composition for preparing the in vitro fed state dissolution medium may comprise a 3- to 60-fold dilutable buffer concentrate.

[0046] In one embodiment, the biorelevant precursor composition of the present invention is a substantially solid / solid-like concentrate, a viscous gel-like concentrate, or a liquid fat dispersion / concentrate, and is selected from the following groups: i) triglycerides and / or diglycerides and / or monoglycerides or any combination thereof (in an amount of 1-70% by weight); ii) lecithin and / or lysolecithin in an amount of 1 to 45% by weight; iii) carbohydrates in an amount of 15-70% by weight; iv) Water or other aqueous medium in an amount of 1 to 70% by weight At least one major component selected from each of The weight ratio of total fat (one or more major components from each of combined groups i) and ii)):total carbohydrate (one or more major components from combined group iii)) is 20:1 to 1:20; A main component having a weight ratio of glyceride:lecithin and / or lysolecithin of 45:1 to 1:45; Additionally, the group including or consisting of: (i) fatty acids (0.01~15% by weight); (ii) bile acids / salts (0.01-3 wt%); (iii) enzymes (0.01-2 wt%); (iv) cholesterol, sterols (0.01-5% by weight); (v) buffering agent (0.01-4 wt%); (vi) Osmotic agent (0.01~8% by weight); (vii) proteins (collagen, protein hydrolysates, amino acids) (0.01-30% by weight); (viii) mucin (0.1-5 wt%); (ix) a viscosity modifier (0.1 to 5% by weight); and (x) preservatives, stabilizers (0.01 to 3% by weight), For example, a) antioxidants, b) a chelating agent; c) a buffer solution (inorganic or organic), and d) Antibacterial agents and at least one additional component selected from at least one member of

[0047] Unless indicated to the contrary, all weight percentages (see above and below) are by dry weight.

[0048] In one embodiment of the present invention, the aqueous medium for dispersing or diluting the biorelevant concentrate composition for preparing the in vitro fed-state dissolution medium comprises: (i) a buffer to reach the required pH, buffering capacity, and osmolality of the biorelevant dissolution medium without further dilution; or (ii) In any order of incorporation and / or dilution, it may include a sufficient weighed / measured amount of biorelevant concentrate, a sufficient weighed / measured amount of buffer concentrate, and purified water to reach the required pH, buffer capacity, and osmolality.

[0049] In another embodiment of the invention, for example, mucins, enzymes (e.g., pepsin and / or pancreatin) and / or proteins and / or amino acids can be added separately to the in vitro biorelevant fed state gastric dissolution medium either during or after preparation of the fed state dissolution medium to reflect high and low fat diet content. Alternatively, the components can also be added to the buffer concentrate or diluted buffer.

[0050] Size reduction and controlled evaporation or titration In another aspect, the present invention provides a process for making precursor concentrates comprising processing dietary components, uniformly dispersing and / or homogenizing and / or controlling the water content from 1.0% to 70.0% by weight by evaporation, e.g. vacuum evaporation or thin film evaporation, dialysis, microwave, and / or addition or titration, resulting in substantially solid / solid-like compositions, viscous gel-like compositions and liquid fat dispersions / concentrates.

[0051] In one embodiment, the substantially solid / solid-like concentrate typically comprises from 1% to 10% by weight of water or aqueous medium.

[0052] In one embodiment, the viscous gel-like concentrate typically comprises 10% to 25% by weight of water or aqueous medium.

[0053] In one embodiment, the liquid fat dispersion concentrate typically comprises 25% to 70% by weight of water or aqueous medium.

[0054] Method for preparing biorelevant in vitro dissolution media from concentrates As described herein, concentrates or biorelevant precursor compositions based on the fat content of recommended FDA standard high or low fat meals and meal replacements can be converted to biorelevant in vitro fed state gastric dissolution media by adding a suitable aqueous medium or diluent. Thus, in one aspect, the present invention further provides a method for making a synthetic biorelevant in vitro fed state dissolution media based on the amount of fat in a high to low fat diet, the method comprising adding an aqueous medium buffered to pH 1.5 to pH 7.5 or adding a buffer concentrate 3-fold to 60-fold to the biorelevant precursor concentrate composition of the present invention. The present invention also provides a synthetic in vitro biorelevant fed state dissolution media comprising the biorelevant precursor concentrate composition of the present invention and an aqueous medium. The present invention also provides a synthetic in vitro biorelevant fed state dissolution media obtainable by adding an aqueous medium to the biorelevant precursor concentrate of the present invention.

[0055] Aqueous media include, for example, purified water, and may also include aqueous solutions of 3-60x buffer concentrates, osmolality components, ethanol, stabilizers, enzyme buffers, etc. The buffers preferably include one or more inorganic or organic buffers selected from the list herein.

[0056] Typically, when the biorelevant concentrate / composition is a liquid fat dispersion concentrate, or a substantially clear to opaque viscous gel-like composition, or a substantially solid / solid-like concentrate, dispersion or dilution in an aqueous medium involves contacting the precursor composition with at least the same amount of aqueous medium. Preferably, the precursor composition is diluted with at least 2 to at least 10 times the volume of the aqueous medium. For media with low fat content, even higher dilution ratios (up to 100 times) are within the scope of the invention.

[0057] The present invention also provides the use of a synthetic in vitro fed state gastric biorelevant dissolution medium for pharmaceutical solubility and dissolution testing for the reference-listed products and supports the in vivo BA / BE studies.

[0058] The present invention provides an in vitro fed state gastric medium for compatibility and stability testing of e.g. probiotics, nutrients, vitamins, and gastric devices such as implants, stents, bands, for ethanol weight control and weight loss and overdose studies, in addition to in vitro solubility and dissolution testing of drugs (new chemical entities and generic drugs) and their dosage forms in a biorelevant medium simulating low fat fed state gastric fluid to investigate the effect of food on drugs. [Brief description of the drawings]

[0059] [Figure 1] 1 shows the results of a dissolution test of exemestane in a simulated gastric medium in the fed state. [Diagram 2] 1 shows the results of a dissolution test of cinnarizine in a simulated gastric medium under fed conditions. [Diagram 3] 1 shows the results of a dissolution test of cinnarizine in a simulated gastric medium under fed conditions. [Figure 4] 1 shows the results of a dissolution test of mefenamic acid capsules in a simulated gastric medium in the fed state. [Diagram 5] 1 shows the results of a dissolution study of mefenamic acid capsules in a simulated gastric medium under fed conditions. [Figure 6]1 shows the results of a dissolution study of danazol capsules in a simulated gastric medium under fed conditions. [Figure 7] 1 shows the results of a dissolution study of danazol capsules in a simulated gastric medium under fed conditions. [Figure 8] 1 shows the dissolution profile of megestrol acetate in FEDGAS pH 3 after various preparation times. [Figure 9] 1 is a transmission electron microscope photograph of FEDGAS media prepared with purified water. [Figure 10] 1 is a freeze-fracture transmission electron microscopy photograph of a biorelevant precursor composition in a viscous gel-like concentrate. [Figure 11] FEDGAS pH 4.5 is shown immediately after preparation (left) and after 24 hours at room temperature (right). [Figure 12] Milk prepared according to Jantratid et. al 2008 is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0060] The compositions of the present invention are synthetic in vitro biorelevant concentrates that model the amount of fat in meals containing various amounts of fat, and the physicochemical properties of gastric fluids that result after consumption of the meal. The fats include triglycerides, diglycerides, monoglycerides, lecithin and / or lysolecithin. The term "biorelevant concentrate / composition" (also referred to herein as "biorelevant precursor concentrate composition") refers to the fact that the biorelevant concentrate composition itself does not necessarily mimic the physiological environment of the stomach. Rather, the biorelevant concentrates that are readily dispersible in water, upon dilution, dispersion or suspension in or with aqueous media, can conveniently prepare a reliable fed-state gastric medium without simple mixing (e.g., magnetic stirrer) and without any high energy input. The resulting medium contains a stable, homogenous fat dispersion that can be easily filtered through a 0.45 micrometer filter. Primarily, the biorelevant medium is for in vitro solubility and dissolution testing to mimic the physiological and physicochemical functions of gastric fluids induced by consumption of a test meal and to confirm the food effect of drugs.

[0061] Substantially solid / solid-like concentrates typically contain from 1% to 10% by weight of water or aqueous medium.

[0062] Viscous gel-like concentrates typically contain 10% to 25% by weight water or aqueous medium.

[0063] Fat dispersions / liquid concentrates typically contain 25% to 70% by weight of water or aqueous medium.

[0064] The biorelevant precursor composition of the present invention is typically provided in a container. Typically, the container is a laminated pouch or sachet. The container may be glass, a suitable plastic bottle (such as, but not limited to, HDPE, PE, PP), a suitable metal bottle (aluminum, stainless steel). Typically, the sachet or pouch contains about 1 g to about 1500 g, for example, about 5 g to about 500 g, of the biorelevant concentrate. For example, containers up to 10 kg can also be used.

[0065] The biorelevant precursor compositions of the invention can be provided in kits with compositions, e.g., solid dissolution compositions and / or concentrated buffers suitable for dispersion, dilution or suspension in aqueous media, inter alia, to mimic the fed state gastric fluids of mammalian species (e.g., humans, dogs, rabbits, rodents, mice, monkeys, and pigs) at a desired physiological pH.

[0066] The kit may also include a filter for separating undissolved drug particles from the filtrate containing the dissolved drug, e.g., selected from glass microfiber, PVDF, nylon, or PES, having a pore size, e.g., of 0.2 to 1 micron, and a prefilter, e.g., having a pore size of 1 to 10 microns.

[0067] As described in more detail herein, the biorelevant concentrate composition of the present invention comprises a mixture of triglycerides and / or diglycerides and / or monoglycerides, and lecithin (diacyl phospholipids) and / or lysolecithin (monoacyl phospholipids) from diacylation, and comprises a homogeneously dispersed fat further comprising carbohydrates and / or sugar alcohols in an aqueous medium, and the water content in the concentrate composition is between 1.0% and 70.0% by weight.

[0068] The compositions of the present invention may also contain a smaller bile salt component (<3.0%) to reflect the consequences of duodenal reflux.

[0069] The biorelevant precursor composition is surprisingly stable and reproducible for preparing a biorelevant in vitro fed-state gastric medium (FEDGAS). We demonstrate how biorelevant precursors with unexpected and surprisingly robust physicochemical properties can be concentrated in ongoing stability studies for more than 9 months at 22°C and at least 9 months at 40°C to create a consistent in vitro fed-state gastric medium for reproducible dissolution testing of drug and (other) industrial applications (see case study 2).

[0070] The predictive and user-friendly properties of the medium are primarily certain physicochemical parameters, e.g. particle size, fat content, buffering capacity, surface tension, osmotic pressure, and the weight ratio of total fat to total carbohydrate content in the medium is 20:1 to 1:20; alternatively or preferably 15:1 to 1:15, or 10:1 to 1:10, or 5:1 to 1:5, or 2:1 to 1:2.

[0071] In vitro surface tensions of gastric dissolution media in the fed state are typically 30-50 mN / m.

[0072] In vitro fed state gastric media is readily filterable, with substantially uniform submicron particles consistently less than 1000 nm, preferably less than 500 nm, more preferably less than 250 nm, even more preferably less than 200 nm, typically less than 175 nm, e.g., 150 nm, with a narrow size distribution and a polydispersity index (pdi) consistently less than 0.2. Consistent physicochemical properties (e.g., particle size, narrow distribution, surface tension, pH compatibility at the physiological pH of fed state gastric fluid between pH 1.5 and pH 7.5, and temperature stability around 37° C. for at least 6 hours) are important.

[0073] Characteristically, the dissolution medium can be easily filtered using a 0.22-10 μm pore size filter, preferably 0.45-1.0 μm. At least 20 mL of dissolution medium can be easily manually filtered using a GE Healthcare Whatman™ GD / X glass microfiber (GMF) syringe filter with a pore size of 0.45 μm. Typically, the Z-average particle size using photon correlation spectroscopy is less than 200 nm, typically 175 nm. The size distribution, as reflected by the polydispersity index, is consistently less than 0.2.

[0074] The biorelevant precursor composition of the present invention is a substantially solid / solid-like concentrate, a viscous gel-like concentrate, or a liquid fat dispersion / concentrate, comprising the following group of main components: i) triglycerides and / or diglycerides and / or monoglycerides or any combination thereof (1-70% by weight, preferably 3-70% by weight, more preferably 5-70% by weight); ii) lecithin and / or lysolecithin (1 to 45% by weight, preferably 1 to 30% by weight, more preferably 1 to 15% by weight); iii) carbohydrates (15-70% by weight, preferably 20-60% by weight); iv) at least one main component selected from water or other aqueous medium (1 to 70% by weight, preferably 1 to 66% by weight, preferably 1 to 60% by weight), wherein the weight ratio of total fat (one or more main components from each of groups i) and ii) combined:total carbohydrates (one or more main components from group iii) combined) is from 20:1 to 1:20, or alternatively preferably from 15:1 to 1:15, or from 10:1 to 1:10, or from 5:1 to 1:5, or from 2:1 to 1:2, and the weight ratio of glycerides:lecithin and / or lysolecithin is from 45:1 to 1:45, or alternatively preferably from 30:1 to 1:30, or from 15:1 to 1:15, or from 10:1 to 1:10, or from 8:1 to 1:8, or from 7:1 to 1:7, or from 7:1 to 1:3, Additionally, the group including or consisting of: (i) fatty acids (0.01 to 15% by weight, preferably 0.1 to 10% by weight); (ii) bile acids / salts (0.01-3% by weight, preferably 0.1-1% by weight); (iii) an enzyme (0.01 to 2% by weight, preferably 0.1 to 1.5% by weight); (iv) cholesterol, sterol (0.01 to 5% by weight, preferably 0.01 to 2.5% by weight); (v) a buffering agent (0.01 to 4% by weight, preferably 0.1 to 2% by weight); (vi) an osmotic agent (0.01 to 10% by weight, preferably 1 to 8% by weight); (vii) proteins (collagen, protein hydrolysates, amino acids) (0.01 to 30% by weight, preferably 0.1 to 25% by weight); (viii) mucin (0.1-5% by weight, preferably up to 2.5% by weight); (ix) viscosity modifier (0.1 to 5% by weight, preferably 0.1 to 2.5% by weight); (x) at least one additional component selected from at least one member of a preservative, a stabilizer (0.01-3 wt %, preferably 0.1-1.5 wt %), such as an antioxidant, a chelating agent, a buffer (inorganic or organic), and an antimicrobial agent.

[0075] Unless indicated to the contrary, all weight percentages (see above and below) are by dry weight.

[0076] Glycerides The biorelevant precursor composition of the present invention may comprise at least one triglyceride in an amount of 1% to 70% by weight, preferably 3% to 70% by weight, preferably 5% to 70% by weight. Any synthetic, semi-synthetic, or natural triglyceride from any plant or animal source / origin may be used. The triglyceride may be liquid or solid at the relevant temperature (15°C to 30°C, e.g., about 20°C). The triglyceride may be selected, for example, from avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, rapeseed oil, safflower oil, sesame oil, soybean oil, sunflower oil, and combinations thereof. Preferred triglycerides include oils that are liquid at 20°C, such as soya oil (soybean oil), olive oil and rapeseed oil, and oils that are solid at 20°C, such as coconut oil and palm oil. Most preferably, the triglycerides include olive oil, avocado oil, palm oil. The triglycerides can be preferably a single oil from the same source or a combination oil from different sources / origins. Natural or semi-synthetic or synthetic medium chain triglycerides (MCTs) containing fatty acids having 6-12 carbons are within the definition of triglycerides in the present invention.

[0077] In a preferred embodiment, the fatty acid profile of the biorelevant dissolution medium contains at least 60% Cl8, but can be matched to the fatty acid profile of different types of diet. The biorelevant precursor composition of the present invention may comprise the product of partial lipolysis of at least one triglyceride component as defined herein.

[0078] The biorelevant precursor composition may further comprise at least one diglyceride. Any suitable diglyceride may be used in an amount of 1% to 70% by weight, preferably 3% to 70% by weight, preferably 5% to 70% by weight. Any diglyceride that is a product of lipolysis of any triglyceride as defined herein may be used. Typically, the diglyceride when used is glyceryl dioleate.

[0079] The biorelevant precursor composition of the present invention may also comprise at least one monoglyceride in an amount of 1% to 70% by weight of the total glycerides, preferably 3% to 70% by weight, preferably 5% to 70% by weight. Furthermore, the amount of monoglyceride, if included, will typically not exceed 50% of the total glycerides. Any suitable monoglyceride may be used; in particular, any monoglyceride that is a product of lipolysis of any triglyceride or diglyceride as defined herein. Typically, the monoglyceride is glyceryl monooleate.

[0080] The biorelevant precursor composition of the present invention may also contain at least one fatty acid at 15% by weight or less. Any suitable fatty acid may be used, in particular any fatty acid that is a product of lipolysis of any triglyceride, diglyceride or monoglyceride as defined herein. Typically, the fatty acid is oleic acid.

[0081] Lecithin and Lysolecithin It should be understood that the description of lecithin includes, among others, phospholipids, which are the main component group of lecithin, along with neutral lipids, such as glycolipids, fatty acids, triglycerides, etc. Phospholipids mainly contain phosphatidylcholine (PC). The purity of phospholipids / lecithin is conventionally related to the amount of PC in the mixture. This mixture may also contain phosphatides, such as, by way of example, phosphatidylinositol, phosphatidylserine, etc.

[0082] Phospholipids (lecithins) have twin hydrocarbon tails and are identified as diacyl phospholipids. The molecule can also have only one hydrocarbon chain and be identified as monoacyl phospholipids. Monoacyl phospholipids are commonly known as lysolecithins. The hydrocarbon chains of lecithins and lysolecithins can be saturated, for example, dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol, and / or unsaturated, for example, dioleoyl phosphatidylcholine. Lecithins and lysolecithins further include hydrogenated lecithins and lysolecithins, for example, hydrogenated soy lecithins. Lecithins and lysolecithins can be synthetic, semi-synthetic, or derived from any vegetable or animal source, including, but not limited to, soybeans, eggs, canola, rapeseed, sunflower, or fish.

[0083] The biorelevant precursor concentrate composition of the present invention comprises one or more phospholipids and / or one or more lysophospholipids as described. Any suitable lecithin (phospholipid) and / or lysophospholipid (lysolecithin) can be used from natural, semi-synthetic, or synthetic sources. Charged phospholipids can improve the stability of dispersed fat aggregates. Phospholipids (lecithin) comprise primarily phosphatidylcholine (PC), as well as small amounts of phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylinositol (PI), and phosphatidylglycerol (PG). Lysophospholipids (lysolecithin) comprise primarily lysophosphatidylcholine, as well as small amounts of monoacyl derivatives of other phosphatides.

[0084] The biorelevant precursor concentrate composition has a phospholipid content, including lecithin and / or lysolecithin, of 1-45% by weight, preferably 1-30% by weight, preferably 1-15% by weight.

[0085] In this mixture, PC may be broadly 15% to 99% by weight. LPC may be 0.5% to 85.0% by weight. Phospholipids containing 30.0% to 95.0% PC and 2.0% to 70.0% LPC are preferred. In the present invention, the terms lecithin and phospholipid are synonymous and include: (i) both lecithin and lysolecithin or phospholipids and lysophospholipids in a mixture; (ii) either lecithin (a phospholipid) or lysolecithin (a lysophospholipid) alone. The combined amount of lecithin and lysolecithin is 30% by weight to 98% by weight.

[0086] carbohydrates The biorelevant precursor concentrate composition of the present invention comprises at least one carbohydrate and / or sugar alcohol. Any suitable carbohydrate, such as a sugar (commonly known as carbohydrate) per se, and / or a suitable sugar alcohol may be used. For example, the sugar / carbohydrate may be selected from the list of monosaccharides, such as fructose, glucose, galactose, mannose, ribose, etc., the list of disaccharides, such as sucrose, lactose, maltose, trehalose, etc., or a combination of monosaccharides and disaccharides.

[0087] The sugar alcohol may be selected from mannitol, lactitol, sorbitol, xylitol, etc. The term sugar alcohol as used herein includes polyols such as glycerol.

[0088] Preferred concentrates themselves comprise a carbohydrate and / or a sugar alcohol selected from glucose, fructose, sucrose, lactose, erythritol, maltitol, isomaltol, mannitol or xylitol. Combinations of carbohydrate(s) and / or sugar alcohol(s) can also be used.

[0089] The main group of carbohydrate components including sugars (carbohydrates), sugar alcohols and combinations thereof in suitable ratios, which may be, for example, a combination of glucose (monosaccharide), fructose (sugar alcohol), sucrose (disaccharide), dextrin or starch (polysaccharide), provide the biorelevant precursor concentrate of the present invention with a water activity of less than 0.86, preferably less than 0.70, thereby inhibiting microbial growth and resulting in excellent long-term storage of the precursor concentrate with less than 10 CFU (Table 2). In the case of solid / solid-like concentrates, the water activity is also less than 0.7. Water activity is a parameter for the industrial applicability and benefits provided by the present invention in the field of biorelevant in vitro dissolution testing and simulation of fed gastric fluids.

[0090] [Table 2]

[0091] If the water activity is greater than 0.86 or the CFU count is greater than, for example, 10 CFU / g, the microbial load of the precursor concentrate composition may be reduced by, for example, but not limited to, pasteurization, UHT, sterile filtration, steam sterilization.

[0092] The biorelevant precursor concentrates of the present invention may further comprise viscosity modifiers such as, but not limited to, oligosaccharides and / or polysaccharides, which may be digestible or non-digestible. For example, the polysaccharides may be starch, modified starch, dextrin, cellulose, polydextrose, pectin, galactomannan, alginate, etc., and / or semi-synthetic types, such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, chitosan, etc.

[0093] The precursor concentrate of the present invention comprises a total fat:carbohydrate ratio within the range of 20:1 to 1:20, preferably 15:1 to 1:15, preferably 10:1 to 1:10, preferably 5:1 to 1:5, preferably 2:1 to 1:2.

[0094] When the readily water-dispersible precursor concentrate is diluted or dispersed in an aqueous medium, the resulting ratio in the gastric dissolution medium of the in vitro biorelevant fed state is maintained.

[0095] fatty acid The biorelevant precursor concentrates of the present invention may contain additional components further including free fatty acids such as oleic acid, lauric acid, linoleic acid, stearic acid and palmitic acid and their salts.

[0096] Bile salts The biorelevant precursor concentrate of the present invention may include additional components, such as bile salts. Any suitable bile salt may be used. Suitable bile salts include sodium cholate, sodium taurocholate, sodium glycocholate, sodium deoxycholate, sodium taurodeoxycholate, sodium glycodeoxycholate, sodium ursodeoxycholate, sodium chenodeoxycholate, sodium taurochenodeoxycholate, sodium glycochenodeoxycholate, sodium cholylsarcosinate, sodium N-methyltaurocholate and their free acids, and combinations thereof. Preferably, the bile salt is selected from sodium cholate, sodium taurocholate, and sodium glycocholate. More preferably, the bile salt is sodium taurocholate.

[0097] buffer solution The biorelevant precursor concentrate of the present invention may contain a buffer and an osmotic agent. However, a buffer, preferably a buffer concentrate or solution, is incorporated / added to the biorelevant concentrate composition or to the dissolution medium simulating in vitro biorelevant feeding conditions. More preferably, the buffer is added using a dilutable concentrate requiring a dilution of 3-60 times, preferably 5-40 times, more preferably 15-30 times.

[0098] The buffer concentrate can be incorporated into the biorelevant concentrate composition. Alternatively, the biorelevant concentrate composition can be incorporated into the buffer concentrate in the reverse order to provide an in vitro fed state dissolution medium with the required pH (pH 1.5-pH 7.5) and buffer capacity (5-100, preferably 10-30, 15-30 mM / ΔpH).

[0099] Additionally, purified water may be added to the mixture containing the biorelevant concentrate and the dilutable buffer concentrate to prepare the in vitro fed state dissolution medium of the present invention at the target pH of pH 1.5 to pH 7.5 required for dissolution testing. The biorelevant precursor concentrate composition, (ii) the buffer concentrate, and (iii) purified water may be added / combined in any order to prepare the in vitro fed state gastric dissolution medium at the pH required for in vitro dissolution testing.

[0100] buffer concentrate A dilutable 25x buffer concentrate containing appropriate amounts of sodium chloride, citric acid and sodium citrate (amounts from Table 6) was prepared by dissolving the buffer and osmotic agent (sodium chloride) in purified water. 900mL of in vitro test medium 1) Weigh out 36.8g of 25x buffer concentrate (pH 3) into a suitable container; 2) adding 732.6 g of purified water; 3) adding 153.0 g of FEDGAS gel; 4) Stirring the dispersion until it is completely uniform. The resulting in vitro test medium has a pH of 3.0 and a buffering capacity of typically 22 mM / ΔpH.

[0101] The buffer concentrate and biorelevant precursor concentrate compositions are placed in separate containers and combined as described for preparing the in vitro fed state gastric medium.

[0102] Two separate containers may be included in the kit, along with filters for, among other things, performing in vitro solubility and dissolution tests.

[0103] Any suitable buffering agent can be used. Suitable buffering agents include at least one inorganic buffering agent selected from monobasic sodium phosphate; acetic acid; hydrochloric acid; maleic acid; citric acid; lactic acid; monobasic potassium phosphate; trisodium citrate; sodium acetate trihydrate; imidazole; sodium carbonate; sodium bicarbonate; sodium cacodylate; sodium barbital; phosphates such as Na2HPO4, NaH2PO4, K2HPO4 and KH2PO4; and sodium hydroxide, and / or 2-(N-morpholino)ethanesulfonic acid (MES), bistrismethane (bistris); 2-[ (2-Amino-2-oxoethyl)-(carboxymethyl)amino]acetic acid (ADA);N-(2-acetamido)-2-aminoethanesulfonic acid (ACES);Bis-trispropane 1,3-bis(tris(hydroxymethyl)methylamino)propane;Piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES);2-(carbamoylmethylamino)ethanesulfonic acid (ACES);2-Hydroxy-3-morpholinopropanesulfonic acid (MOPSO);Coramine chloride;Coramine chloride hydrochloride;3-Morpholinopropane-1-sulfonic acid (MOPS);N N-Bis(2-hydroxyethyl)amino-2-hydroxypropane-1-sulfonic acid (BES);2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid (TES);2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES);[3-bis(2-hydroxyethyl)amino-2-hydroxypropane-1-sulfonic acid](DIPSO);[3-bis(2-hydroxyethyl)amino-2-hydroxypropane-1-sulfonic acid]MOBS;Acetamide Glycine;3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]-2-hydroxypropane-1-sulfonic acid (TAPSO);2,2',2''-Nitrilotris(ethan-1-ol) (TEA);Piperazine-N,N'-bis(2-hydroxypropanesulfonic acid) (POPSO);4-(2-hydroxyethyl)piperazine-1-(2-hydroxypropanesulfonic acid) (HEPPSO);4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (HEPPS);N-[Tris(hydroxymethyl)methyl]glycine (Tricine);Tris(hydroxymethyl)aminomethane (Tris);Glycinamide;Glycine;Glycylglycine;Histidine;N-(2-hydroxyethyl)piperazine-N'-(4-butanesulfonic acid) (HEPBS);2-(Bis(2-hydroxyethyl)amino)acetic acid (Bicine);[Tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS);2-Amino-2-methyl-1-propanol (AMPB);2-(Cyclohexylamino) At least one organic buffer is selected from ethanesulfonic acid (CHES); beta-aminoisobutyl alcohol (AMP); N-(1,1-dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid (AMPSO); 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid, CAPSO free acid (CAPSO); 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS); and 4-(cyclohexylamino)-1-butanesulfonic acid (CABS).

[0104] Osmotic agents Osmotic agents are included to adjust the osmotic pressure of the dissolution medium to mimic the osmotic pressure of fed state gastric fluid after a meal, such as an FDA diet. Osmotic agents typically include, but are not limited to, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, hydrochloric acid, and sodium hydroxide (including combinations thereof). Carbohydrates and buffers may also contribute to the overall osmotic pressure of the in vitro dissolution medium. Osmotic agents may be incorporated into the biorelevant precursor concentrate composition, or preferably into the buffer concentrate. The osmotic pressure range of the fed state dissolution medium is 200-800 mOsm / L, typically 300-600 mOsm / L. After a meal, the osmotic pressure of gastric fluid in the stomach after a high fat meal is usually higher than after a low fat meal. Additionally, the osmotic pressure may be affected by the food content and residence time in the fed stomach. The osmotic pressure of in vivo fed state gastric fluid that can be mimicked in the in vitro fed state gastric medium of the present invention is typically 400-550 mOsm / L.

[0105] enzyme If desired, additional components, for example enzymes such as gastric lipase and / or pepsin, may be added to the actual dissolution medium rather than to the concentrate.

[0106] Preservatives and stabilizers Examples of antioxidants include, but are not limited to, ascorbic acid, ascorbyl palmitate, vitamin E and esters, carotenoids, vitamin A. Chelating agents include, but are not limited to, dimercaprol, disodium EDTA, desferrioxamine, citrate. Buffers (inorganic or organic) are as described in the buffer section. Antimicrobial agents include, but are not limited to, thimerosal, sodium azide, butylated hydroxytoluene, butylated hydroxyanisole, sorbic acid.

[0107] In one preferred biorelevant precursor concentrate composition: i) the at least one triglyceride is selected from soybean oil, olive oil, rapeseed oil, coconut oil, avocado oil and palm oil; ii) the at least one diglyceride is selected from glycerol dioleate, glycerol distearate, glycerol dilaurate, and linoleic acid diglyceride; iii) the at least one monoglyceride is selected from glycerol monooleate, glyceryl monostearate, glycerol monolaurate, and linoleic acid monoglyceride; iv) at least one component selected from lecithin and / or lysolecithin comprises at least 40% phospholipids and / or at least 40% by weight lysophospholipids; vi) the at least one carbohydrate and / or sugar alcohol comprises glucose and fructose and / or sorbitol; vii) the at least one polysaccharide comprises starch, modified starch and / or dextrin; wherein the total fat:total carbohydrate ratio is 20:1 to 1:20, preferably 15:1 to 1:15, preferably 10:1 to 1:10, preferably 5:1 to 1:5, preferably 2:1 to 1:2; and further wherein the glyceride:lecithin and / or lysolecithin ratio is 45:1 to 1:45, preferably 30:1 to 1:30, preferably 15:1 to 1:15, preferably 10:1 to 1:10, preferably 8:1 to 1:8, preferably 7:1 to 1:7, preferably 7:1 to 1:3.

[0108] In a particularly preferred biorelevant precursor composition: i) at least one triglyceride comprises olive oil; ii) the at least one diglyceride comprises glycerol dioleate; iii) the at least one monoglyceride comprises glycerol monooleate; iv) at least one component selected from lecithin and / or lysolecithin comprises at least 15% by weight of phosphatidylcholine (PC) and / or at least 0.5% of lysophosphatidylcholine (LPC); vi) the at least one carbohydrate comprises glucose, fructose, and sucrose; vii) the at least one polysaccharide comprises dextrin; Here, the total amount of fat:carbohydrate is 20:1 to 1:20, preferably 15:1 to 1:15, preferably 10:1 to 1:10, preferably 5:1 to 1:5, preferably 2:1 to 1:2; furthermore, the ratio of glyceride:lecithin and / or lysolecithin is 45:1 to 1:45, preferably 30:1 to 1:30, preferably 15:1 to 1:15, preferably 10:1 to 1:10, preferably 8:1 to 1:8, preferably 7:1 to 1:7, preferably 7:1 to 1:3.

[0109] Modification of the biorelevant precursor compositions of the present invention may be performed to meet desired physicochemical, particularly fat content, of the composition, for example modification of the standard FDA high fat diet.

[0110] It is within the scope of the present invention to adjust and select the total fat and carbohydrate content in the concentrate to prepare a dissolution medium that mimics the fed state gastric medium modeled after a meal having a target fat value.

[0111] Typically, the water content of the composition is controlled between 1.0% and 25.0% to form either a substantially solid / solid-like and gel-like liquid concentrate. Removal of water by evaporation can be, for example, vacuum assisted, or by freeze-drying, e.g., lyophilization.

[0112] The content of bile salt(s) in the composition of the present invention is based on the amount of intestinal fluid refluxed from the duodenum. If present, the amount of bile salt in the composition of the present invention is less than 3.0% by weight, typically less than 1.0% by weight.

[0113] By way of example and not of limitation, the following are typical examples illustrating the invention. Typical examples of concentrate compositions are shown in Table 3 with typical ranges of ingredients. The compositions may contain lecithin and / or lysolecithin with different PC content (purity) in the mixture.

[0114] Freeze-fracture of a viscous gel-like precursor of a biorelevant concentrate is shown in FIG.

[0115] Examples of actual dissolution media are shown in Table 8.

[0116] [Table 3]

[0117] Preparation and composition of in vitro dissolution media prepared from biorelevant concentrate compositions shown in Table 3.

[0118] The amount of total fat in the biorelevant precursor concentrates of the present invention is typically such that when the precursor is dispersed, diluted, or suspended in an aqueous medium to obtain a biorelevant medium, a fat concentration of 0.5% to 20% w / v is obtained.

[0119] More typically, the amount of fat in the biorelevant precursor concentrate is such that when the precursor composition is dispersed, diluted, or suspended in an aqueous medium to obtain a biorelevant medium modeled after the FDA recommended standard dietary variations of high and low fat amounts, a fat concentration of 4.0% w / v to 20.0% w / v, preferably 5% to 15% w / v, preferably 6% to 10% w / v is obtained. Additionally, the amount of fat and the amount used may be adjusted and selected to take into account other variations, i.e., medium fat, low fat variations, with very high fat contents up to 15% and very low fat contents down to 0.1% not outside the scope of the present invention.

[0120] Table 3 shows the main ingredients of a typical concentrate composition according to the invention. Variable fat content of the desired in vitro test medium can be obtained by selecting the ingredients and adjusting the amounts in Table 3, thereby providing a concentrate composition for dilution and preparation of test medium for in vitro dissolution, solubility and stability testing of drugs and pharmaceuticals. Testing with in vitro dissolution media also evaluates the potential food effect on drugs and pharmaceuticals due to fat content at physiological pH of the stomach or from fat-containing beverages / drinks, e.g. tea with full fat milk or reduced fat milk.

[0121] Exemplary Methods for Preparing Precursor Compositions Step 1

[0122] The following ingredients are weighed into a suitable reactor or processing vessel: -66kg of purified water ** Stabilizer 0.8kg ** any

[0123] Suitable reactors include, but are not limited to, evaporator, thin film evaporator, microwave, optionally vacuum assisted. The solution is stirred at 50-10000 RPM, preferably 50-2000 RPM, preferably 50-500 RPM, and maintained at 15-80°C, preferably 30-80°C, more preferably 40-70°C. Step 2

[0124] When the solution from step 1 is homogeneous, add the following ingredients: *** Lecithin 4.50kg -Bile salts 0.16kg *** Lecithin and / or lysolecithin.

[0125] The suspension of step 2 is stirred at 50-30000 RPM, preferably 100-10000 RPM, preferably 200-5000 RPM, at a temperature of 15-80° C., preferably 40-70° C. A light vacuum is maintained until all ingredients are fully hydrated. Step 3

[0126] When the suspension from step 2 is uniform, add the next ingredient: **** Glycerides 28kg **** Triglycerides Step 4

[0127] The suspension of step 3 is stirred at 50-30000 RPM, preferably 100-10000 RPM, preferably 200-5000 RPM at a temperature of 15-80°C, preferably 30-80°C, preferably 40-70°C. A light vacuum is maintained until all ingredients are thoroughly mixed. A homogeneous fat dispersion with particle size of about 0.5-5 microns is obtained. Step 5

[0128] The fat dispersion of step 4 may be further processed using a homogenizer selected from a high shear mixer, high pressure, microfluidizer, ultrasonic or any other suitable high energy homogenizer.

[0129] A yield of 99.5 kg of homogenized fat dispersion from step 5 and the ingredients shown in Table 4 is obtained with a Z-average diameter of 1000 nm, typically less than about 500 nm.

[0130] The homogenized fat dispersion is transferred to a suitable storage tank or container.

[0131] [Table 4] Step 6

[0132] The following ingredients are added to the reactor in Step 1: carbohydrates *** 22.10kg Dextrin 1.16kg *** Invert sugar

[0133] The solution is stirred and heated to 20-80° C., typically 50-70° C. A vacuum is applied to initiate evaporation, typically 10-1000, preferably 50-200 mbar. The water content at this stage is 1-70% by weight, typically 15-30% by weight. Step 7

[0134] The homogenized fat dispersion previously stored in a storage tank is added continuously to the reactor. The fat dispersion is added at a controlled flow rate of 0.1-10 l / min, e.g., 0.1-5 l / min, such that the vacuum evaporation rate is 10-1000 mbar. During the continuous addition of the homogenized fat dispersion, the water content of the mixture in the suitable reactor is maintained between 5% and 70%, preferably between 10-40%.

[0135] At the end of step 7, the concentrate composition is in the form of a substantially solid / solid-like concentrate, a substantially gel-like concentrate, or a liquid fat dispersion / concentrate, depending on the targeted water content (generally 1-70% by weight, 10%-25% for the viscous gel-like concentrates shown in Table 5). For solid / solid-like concentrates, the water content is typically 1.0%-10.0%, and for fat dispersions / liquid concentrates, the water content is 25%-70%.

[0136] [Table 5]

[0137] Packaging of the Precursor Composition The gel-like concentrate / composition obtained in step 7 is filled into a suitable container, which may be, but is not limited to, a sachet, a pouch, a suitable plastic bottle (HDPE, PE, PP, etc.), a suitable metal bottle (aluminium, stainless steel, etc.).

[0138] The composition is preferably packed under vacuum or sealed under an inert gas blanket, such as nitrogen.

[0139] The gel-like concentrate may be filled and / or packed into suitable containers for single or multi-dose, for example up to 10 kg capacity.

[0140] Preparation of biorelevant media The synthetic aqueous biorelevant medium is obtained by adding an aqueous medium to the biorelevant gel-like composition / concentrate of Table 5 as described in the manufacturing method. The aqueous medium includes, but is not limited to, for example, purified water, aqueous medium with buffer, osmotic components. The citrate buffer shown in the examples can be replaced with other combinations, for example, acetate buffer at pH 5 and phosphate buffer at pH 3. Additional components, for example enzymes such as gastric lipase, can also be present with the osmotic agent and buffer in the eluted composition of the present invention.

[0141] Typically, biorelevant dissolution media is prepared from the concentrates in Table 5 as follows, for example to make 900 ml of media for a high fat FDA diet: 1-Add about 600 g of water and appropriate buffer components for the desired pH to a vessel. 2-Add 152.3 g of the concentrate shown in Table 5 to a container. 3-Add remaining purified water (total water 763.62 g) to make up to volume. 4- Add a magnetic stirrer and keep stirring until all ingredients are thoroughly mixed. 5-Check the pH to 4.5.

[0142] The following typical examples in Tables 6, 7, and 8 can be obtained using the above preparation methods.

[0143] [Table 6]

[0144] [Table 7]

[0145] [Table 8]

[0146] As shown in Table 9A, the dissolution medium can also be prepared by weighing the individual components separately into a buffer solution and then homogenizing.

[0147] [Table 9A]

[0148] The biorelevant dissolution medium shown in Table 9B is prepared as follows, for example to make 900 ml of low-fat FDA diet medium. 1-Add about 600 g of water and appropriate buffer components for the desired pH to a vessel. 2-Add 76.15 g of the concentrate of Table 5 to a container. 3- Add remaining purified water to make up to volume (a total of 889g of water should be added). 4- Add a magnetic stirrer and keep stirring until all ingredients are thoroughly mixed. 5-Check the pH to 4.5.

[0149] [Table 9B]

[0150] The biorelevant dissolution medium shown in Table 10 is prepared as follows, for example to make 900 ml of double high fat FDA diet medium. 1-Add approximately 500 g of water and appropriate buffer components for the desired pH to a vessel. 2-Add 304.59 g of the concentrate of Table 5 to a container. 3- Add remaining purified water to make up to volume (a total of 610.33g of water should be added). 4- Add a magnetic stirrer and keep stirring until all ingredients are thoroughly mixed. 5-Check the pH to 4.5.

[0151] The following typical examples in Table 10 were obtained using the preparation methods described above.

[0152] [Table 10]

[0153] Table 11 shows typical physicochemical properties of the previously prepared vehicles.

[0154] [Table 11]

[0155] Biorelevant dissolution media to mimic fed-state gastric juices Biorelevant dissolution media can also be made from scratch by combining all the components in Table 5 with a given amount of water to achieve the target content of the biorelevant dissolution media. The fat content of this media can vary from 20 to 100 grams per 500 ml of media (USP Dissolution Apparatus 2) depending on the amount of concentrate used in Table 5 and the dose of drug in the dissolution test. Buffer salts and additional components can be added before or after the lipophilic components are dissolved or suspended in the aqueous media.

[0156] However, dissolution media made from scratch do not have the stability and storage characteristics of concentrates. Therefore, media prepared from scratch must be used within 24 hours as they are prone to microbiological, physical and chemical spoilage. This makes them unsuitable and unfit for purpose as dissolution media in terms of reliability, consistency and reproducibility.

[0157] Case studies The case studies reported below demonstrate the utility of the present invention in assessing intragastric food effects on pharmaceutical agents.

[0158] In case studies 1 to 4, FEDGAS media of pH 6, pH 5, and pH 3 were prepared by adding the appropriate amount of purified water to a suitable container, adding the corresponding buffer concentrate, adding the appropriate amount of biorelevant precursor concentrate, and mixing with a magnetic stirrer until homogenous.

[0159] Case Study 1 - Dissolution of Exemestane (25 mg) Tablets (Brand Name: Aromasin, a Poorly Soluble Neutral Compound Immediate Release Formulation) The compositions of Table 5 were used to generate three biorelevant fed state gastric media: pH 6, pH 5 and pH 3.

[0160] The media at these three pHs were characterized by measuring pH, buffering capacity, particle size (Z-average and polydispersity using a Nanosizer) and surface tension (Kruss surface tension K6).

[0161] The medium was stable at time zero and physically stable after 24 hours, and the main physicochemical properties were unchanged after 24 hours.

[0162] Dissolution of exemestane (4 x 25 mg tablets) in the media was performed using a USP2 dissolution apparatus at 75 rpm (n=6 vessels). Samples of the three biorelevant media were taken from the dissolution vessels, filtered through 0.45 micrometer nylon filters with prefilters at 5, 10, 15, 20, 25, 30, 45, 60, 90, and 120 minutes, and analyzed for exemestane content by HPLC.

[0163] The results of these dissolution tests are shown in FIG.

[0164] Consistent with exemestane's neutral chemical structure, as can be seen, exemestane was insensitive to different pH and the three dissolution profiles were very similar: within 30 minutes, more than 80% of the drug was dissolved in the three media.

[0165] Case Study 2 - Fed-state simulated gastric concentrate stored at 40°C for 9 months The biorelevant concentrates were stored at 22°C and 40°C for 9 months and the study in case study 1 was repeated with media prepared from the stored precursor concentrates. The ease of dispersion of the fresh and stored precursor concentrates in aqueous media was very similar.

[0166] Unexpectedly, the dissolution profiles of the test media at the three pHs were found to be the same as when the media was prepared from freshly made precursor concentrates.

[0167] Case Study 3 - Dissolution of Cinnarizine (a Basic Drug) The dissolution of Stugeron (15 mg cinnarizine immediate release tablet) was tested in fasted gastric medium (control experiment) and compared to fed gastric medium at pH 6, pH 5, and pH 3 using the same dissolution settings as above.

[0168] The dissolution profile in fasted state gastric medium is shown in FIG.

[0169] The dissolution profile of this drug in fasted gastric medium shows that the basic drug cinnarizine dissolves rapidly in the fasted stomach. The controlled experiment shows that nearly 90% of the drug is dissolved within 30 minutes.

[0170] In contrast, this basic drug exhibits slower drug dissolution in all fed state gastric media (in the pH range from pH 6 to pH 3) as shown in Figure 3. Cinnarizine dissolution also tends to be faster at lower pH (i.e., longer residence time of the drug in the simulated fed state media increases the dissolution rate), reflecting the pH of the gastric fluid towards the end of gastric emptying.

[0171] These in vitro dissolution profiles can be further used with modeling software to better mimic the behavior of the drug in the stomach and how the drug (dissolved or suspended) is presented to the small intestine when the stomach is emptied. Combined with dissolution profiling in small intestinal fluids (fed and fasted), these inputs can become more accurate predictors of in vitro in vivo correlations leading to more efficient development of pharmaceutical products.

[0172] Case Study 4 - Dissolution of Mefenamic Acid (an acidic drug) Dissolution of mefenamic acid hard gelatin capsules was performed in fasted state gastric medium (control) and compared to biorelevant fed state gastric medium at pH 6, pH 5, and pH 3 as described using the set-up and methods of case study 1.

[0173] Referring to Figure 4, dissolution in fasted gastric media is negligible even after 2 hours of dissolution. Even after 2 hours of dissolution, less than 0.1% of the drug dose is dissolved.

[0174] In sharp contrast to the fasted state gastric medium, dissolution of mefenamic acid proceeds much more rapidly in the biorelevant fed state gastric medium (see FIG. 5). Dissolution reaches approximately 45%, 25%, and 10% of the dosage form within 30 minutes in fed state gastric media of pH 6 (simulating fed conditions immediately after ingestion of an FDA high-fat meal), pH 5 (simulating fed conditions approximately 1-3 hours after ingestion of an FDA high-fat meal), and pH 3 (simulating fed conditions approximately 4-5 hours after ingestion of an FDA high-fat meal), respectively.

[0175] Case Study 5-Dissolution of Danazol Capsule Acid (Neutral Drug) Dissolution of danazol (100 mg) hard gelatin capsules was performed in fasted state gastric medium (control) and compared to biorelevant fed state gastric medium at pH 6, pH 4.5, and pH 3 as described using the set-up and methods of case study 1.

[0176] Referring to Figure 6, dissolution in fasted gastric media is negligible even after 2 hours of dissolution. Less than 0.2% of the drug dose is dissolved even after 2 hours of dissolution.

[0177] In sharp contrast to the fasted state gastric medium, dissolution of danazol proceeds much more rapidly in the biorelevant fed state gastric medium (see FIG. 7). Dissolution reaches approximately 55% of the dosage form within 60 minutes in fed state gastric media at pH 6, pH 4.5, and pH 3, respectively.

[0178] Case Study: Investigation of the Physicochemical Properties of FEDGAS Dissolution Media Stored at Room Temperature for 72 Hours Along with the Dissolution of 6-Megestrol Acetate Capsules FEDGAS media at pH 6, pH 4.5, and pH 3 were prepared by adding the appropriate amount of water to a suitable container, adding the corresponding buffer concentrate, adding the appropriate amount of the biorelevant precursor concentrate that disperses easily in water, and mixing with a magnetic stirrer until homogenous. The three media were stored at room temperature for up to 72 hours. Dissolution into each media at t=0, t=24 hours, t=48 hours, and t=72 hours after media preparation was performed using megestrol acetate capsules (160 mg) in 900 mL of media in a container. The results of the dissolution test are shown in Figure 8. The pH, buffer capacity, surface tension, and particle size (Z-average) of FEDGAS pH 6 and FEDGAS pH 3 were measured at t=0 and t=72 hours. The results are shown in Table 12.

[0179] The results show that the dissolution profiles of megestrol acetate hard gelatin capsules in all three vehicles at the four time points were identical. This study shows that the three vehicles did not age after three days of storage. The pH, buffering capacity, surface tension, and particle size at t=72 hours were close to the values ​​at t=0 hours.

[0180] [Table 12]

[0181] The present invention provides a biorelevant dissolution composition and method to obtain simulated media from precursor concentrates for in vitro dissolution and solubility testing. The simulated gastric media models the gastric contents after consumption of high and low fat meals and meal replacements, and contains higher fat (up to 200 g fat) and lower fat amounts (1 g fat). The present invention meets the practical need for fed state biorelevant testing along with fasted state media, which allows for more accurate in vitro evaluation of post-meal intake, such as food effects on drugs after FDA standard meals. Food effects also include in vitro dissolution testing of pharmaceuticals in simulated gastric fluid (FEDGAS) containing 1 g fat, e.g., in a cup of milk tea, supporting improved in vitro-in vivo correlation. In particular, the use of biorelevant media, rather than prior art media, to characterize pharmacologically active / related substances, such as drug compounds, oral dosage forms, etc., is compelling and advantageous. Furthermore, studying the effect of food in the stomach fulfills a practical need for drug characterization, e.g., in lead optimization and general formulation development, thereby leading to cost and time savings.

[0182] The present invention provides a biorelevant concentrate composition that is unexpectedly stable and easily dispersible in water. The biorelevant concentrate and buffer concentrate compositions can be used to produce an easily filterable and surprisingly stable biorelevant test medium that mimics fed-state gastric fluid, for example, after consumption of a high-fat to low-fat FDA meal. This makes the present invention clearly advantageous and of industrial applicability. The proposed fed-state simulated gastric fluid can be used for biorelevant dissolution and solubility testing for drug and pharmaceutical profiling.

Claims

1. 1. A biorelevant precursor composition that is suitable when dispersed, diluted, or suspended in an aqueous medium to simulate fed-state gastric fluids of a mammalian species, said biorelevant precursor composition comprising a substantially solid or solid-like concentrate, a viscous gel-like concentrate, or a liquid fat dispersion or concentrate; i) triglycerides and / or diglycerides and / or monoglycerides or any combination thereof in an amount of 1-70% by weight; ii) lecithin and / or lysolecithin in an amount of 1-45% by weight; iii) carbohydrates in an amount of 15-70% by weight; iv) water or other aqueous medium in an amount of 1 to 70% by weight; At least one principal component selected from each of a group of principal components comprising: the weight ratio of total fat composed of one or more major components from each of groups i) and ii) combined to total carbohydrate composed of one or more major components from group iii) combined is from 20:1 to 1:20; A main component having a weight ratio of glyceride:lecithin and / or lysolecithin of 45:1 to 1:45; moreover, (i) 0.01 to 15 wt. % of a fatty acid; (ii) 0.01 to 3% by weight of a bile acid or salt; (iii) 0.01 to 2 wt. % of an enzyme; (iv) 0.01 to 5% by weight of a sterol; (v) 0.01 to 4% by weight of a buffering agent; (vi) 0.01 to 10 wt. % of an osmotic agent; (vii) 0.01 to 30 wt. % of a protein or protein hydrolysate; (viii) 0.1 to 5% by weight of mucin; (ix) 0.1 to 5 wt. % of a viscosity modifier, and (x) 0.01 to 3% by weight of a preservative or stabilizer; All percentages are by weight of the composition.

2. The composition described in claim 1, wherein the sterol is cholesterol.

3. The composition described in claim 1, wherein the protein is collagen.

4. The composition described in claim 1, wherein the protein hydrolysate is an amino acid.

5. The preservative or stabilizer a) antioxidants, b) a chelating agent; c) an inorganic or organic buffer, and and d) at least one additional component selected from at least one of the following: an antimicrobial agent.

6. 2. The composition of claim 1, wherein the triglyceride is selected from avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, rapeseed oil, safflower oil, sesame oil, soybean oil, sunflower oil, and combinations thereof.

7. The composition of claim 1 , wherein the carbohydrate comprises a polysaccharide, an oligosaccharide, a disaccharide, a monosaccharide and / or a sugar alcohol.

8. The composition described in claim 7, wherein the carbohydrate is selected from glucose, fructose and sucrose, and the polysaccharide is selected from starch, dextrin and cellulose.

9. a) a solid or solid-like concentrate comprising 1% to 10% by weight of water or an aqueous medium; or b) a viscous gel-like aqueous concentrate comprising 10% to 25% by weight of water or an aqueous medium; or c) Liquid emulsion concentrates containing 25% to 70% by weight of water or an aqueous medium. The composition of claim 1 in the form of:

10. The composition of claim 1 , wherein the biorelevant precursor composition has a water activity of less than 0.

86.

11. The composition of claim 10, wherein the biorelevant precursor composition has a water activity of less than 0.

70.

12. A method for producing a biorelevant precursor composition according to any one of claims 1 to 11, said method comprising: i) 1 to 70% by weight of at least one triglyceride, and / or at least one diglyceride and / or at least one monoglyceride; ii) 1 to 45% by weight of at least one lecithin and / or lysolecithin; iii) 15-70% by weight of at least one carbohydrate; iv) 1-70% water or other aqueous medium; wherein the ratio of total fat:total carbohydrates comprised of the combined components i) and ii) is between 20:1 and 1:20, and the ratio of glycerides:lecithin and / or lysolecithin is between 45:1 and 1:45; moreover, (i) 0.01 to 15 wt. % of a fatty acid; (ii) 0.01 to 3% by weight of a bile acid or salt; (iii) 0.01 to 2 wt. % of an enzyme; (iv) 0.01 to 5% by weight of a sterol; (v) 0.01 to 4% by weight of a buffering agent; (vi) 0.01 to 10 wt. % of an osmotic agent; (vii) 0.01 to 30 wt. % of a protein or protein hydrolysate; (viii) 0.1 to 5% by weight of mucin; (ix) 0.1 to 5 wt. % of a viscosity modifier, and (x) 0.01 to 3% by weight of a preservative or stabilizer; by dispersing and / or homogenizing and / or evaporating and / or controlling the water content by addition or titration to obtain a substantially solid or solid-like concentrate, a viscous gel-like concentrate, or a liquid fat dispersion / concentrate.

13. The method of claim 12, wherein the sterol is cholesterol.

14. The method of claim 12, wherein the protein is collagen.

15. The method of claim 12, wherein the protein hydrolysate is an amino acid.

16. The preservative or stabilizer is a) antioxidants, b) a chelating agent; c) an inorganic or organic buffer, and and d) at least one additional component selected from at least one of the following: an antimicrobial agent.

17. 13. The method of claim 12, comprising the use of controlled evaporation after addition of the water containing at least one carbohydrate or directly controlling the addition of the water containing at least one carbohydrate.

18. A method for producing a composition suitable for simulating fed state gastric fluids of a mammalian species, comprising dispersing, diluting or suspending a biorelevant precursor composition according to any one of claims 1 to 11 in an aqueous medium.

19. 20. The method of claim 18, comprising dispersing or diluting the biorelevant precursor composition in aqueous media or buffer concentrates which can be added / combined in any order to prepare an in vitro fed state gastric dissolution medium at the pH required for in vitro dissolution testing.

20. The aqueous medium for dispersing or diluting the biorelevant precursor composition for preparing an in vitro fed-state dissolution medium, comprising: (i) a buffer to reach the required pH, buffering capacity, and osmolality of the biorelevant dissolution medium without further dilution; or 20. The method of claim 19, which may include, in any order of incorporation and / or dilution, a sufficient weighed or measured amount of the biorelevant precursor composition, a sufficient weighed or measured amount of the buffer concentrate, and purified water to reach the required pH, buffer capacity, and osmolality.

21. 20. The method of preparing a fed state gastric medium of claim 18, further comprising adding as a separate step enzymes, protein hydrolysates and / or other additional ingredients.

22. 19. The method of claim 18, wherein the resulting dissolution medium can be easily filtered using a 0.22-10 μm pore size filter, has a Z-average particle size using photon correlation spectroscopy of less than 200 nm, typically 175 nm, and a size distribution as reflected by a polydispersity index consistently less than 0.

2.

23. 12. A kit for use in the manufacture of a composition suitable for simulating fed state gastric fluids of a mammalian species, comprising an aqueous medium or buffer concentrate in a first container and a biorelevant precursor composition according to any one of claims 1 to 11 in a second container.

24. 12. A method of making a synthetic biorelevant in vitro fed state dissolution medium based on the amount of fat in a high to low fat diet, comprising adding an aqueous medium buffered to pH 1.5 to pH 7.5 or adding a buffer concentrate 3x to 60x to a biorelevant precursor composition according to any one of claims 1 to 11.

Citation Information

Patent Citations

  • pH-dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions thereof, and the manufacture and use thereof.

    JP2014531460A

  • Dissolution composition for examining drug solubility

    US20130055831A1

  • Dissolution composition for examining drug solubility

    US20160299113A1